Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase

Journal of Clinical Investigation

Volumn 116, Issue 5, 2006, Pages 1410-1424

  Borrell Pagès, Maria ^a   Canals, Josep M ^b   Cordelières, Fabrice P ^a   Parker, J Alex ^c   Pineda, José R ^b   Grange, Ghislaine ^a   Bryson, Elzbieta A ^a   Guillermier, Martine ^d   Hirsch, Etienne ^e   Hantraye, Philippe ^d   Cheetham, Michael E ^f   Néri, Christian ^c   Alberch, Jordi ^b   Brouillet, Emmanuel ^d   Saudou, Frédéric ^a,g   Humbert, Sandrine ^a  

^a CNRS   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CENTRE PAUL BROCA   (France)

^d DIF   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLATHRIN; CYSTAMINE; HEAT SHOCK PROTEIN; HUNTINGTIN; MERCAPTAMINE; PROTEIN DNAJ; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; GOLGI COMPLEX; HUNTINGTON CHOREA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; STRIATE CORTEX;

AGED; ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CAENORHABDITIS ELEGANS; CYSTAMINE; CYSTEAMINE; HSP40 HEAT-SHOCK PROTEINS; HUMANS; HUNTINGTON DISEASE; MACACA; MICE; MICE, TRANSGENIC; MIDDLE AGED; MOLECULAR CHAPERONES; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; TRANSGLUTAMINASES;

EID: 33646421164     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27607     Document Type: Article

References (70)

1. Young, A.B. 2003. Huntingtin in health and disease. J. Clin. Invest. 111:299-302. doi:10.1172/JCI200317742.
2. MacDonald, M.E., Gines, S., Gusella, J.F., and Wheeler, V.C. 2003. Huntington's disease. Neuromolecular Med. 4:7-20.
3. Melino, G., and Piacentini, M. 1998. 'Tissue' transglutaminase in cell death: a downstream or a multifunctional upstream effector? FEBS Lett. 430:59-63.
4. Lesort, M., Tucholski, J., Miller, M.L., and Johnson, G.V. 2000. Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog. Neurobiol. 61:439-463.
5. Green, H. 1993. Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell. 74:955-956.
6. Cooper, A.J.L., et al. 1997. Polyglutamine domains are substrates of tissue transglutaminase - does transglutaminase play a role in expanded Cag/Poly-Q neurodegenerative diseases? J. Neurochem. 69:431-434.
7. Kahlem, P., Green, H., and Djian, P. 1998. Transglutaminase action imitates Huntington's disease: selective polymerization of huntingtin containing expanded polyglutamine. Mol. Cell. 1:595-601.
8. Karpuj, M.V., et al. 1999. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl. Acad. Sci. U. S. A. 96:7388-7393.
9. Lesort, M., Chun, W., Johnson, G.V., and Ferrante, R.J. 1999. Tissue transglutaminase is increased in Huntington's disease brain. J. Neurochem. 73:2018-2027.
10. Dedeoglu, A., et al. 2002. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22:8942-8950.
11. Karpuj, M.V., et al. 2002. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8:143-149.
12. Zainelli, G.M., Ross, C.A., Troncoso, J.C., and Muma, N.A. 2003. Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J. Neuropathol. Exp. Neurol. 62:14-24.
13. Mastroberardino, P.G., et al. 2002. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 9:873-880.
14. Bailey, C.D., and Johnson, G.V. 2005. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J. Neurochem. 92:83-92.
15. Wang, X., et al. 2005. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J. Neurol. Sci. 231:57-66.
16. Bailey, C.D., and Johnson, G.V. 2005. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol. Aging. doi:10.1016/j. neurobiolaging.2005.04.001.
17. Pinto, J.T., et al. 2005. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. J. Neurochem. 94:1087-1101.
18. Lesort, M., Lee, M., Tucholski, J., and Johnson, G.V. 2003. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278:3825-3830.
19. Fox, J.H., et al. 2004. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 91:413-422.
20. Opal, P., and Zoghbi, H.Y. 2002. The role of chaperones in polyglutamine disease. Trends Mol. Med. 8:232-236.
21. Bonini, N.M. 2002. Chaperoning brain degeneration. Proc. Natl. Acad. Sci. U. S. A. 99:16407-16411.
22. Muchowski, P.J., and Wacker, J.L. 2005. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 6:11-22.
23. Sherman, M.Y., and Goldberg, A.L. 2001. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 29:15-32.
24. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M.E. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 95:55-66.
25. Zuccato, C., et al. 2001. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 293:493-498.
26. Canals, J.M., et al. 2004. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24:7727-7739.
27. Gauthier, L.R., et al. 2004. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 118:127-138.
28. Trettel, F., et al. 2000. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9:2799-2809.
29. Chapple, J.P., and Cheetham, M.E. 2003. The chaperone environment at the cytoplasmic face of the endoplasmic reticulum can modulate rhodopsin processing and inclusion formation. J. Biol. Chem. 278:19087-19094.
30. Sakahira, H., Breuer, P., Hayer-Hartl, M.K., and Hartl, F.U. 2002. Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc. Natl. Acad. Sci. U. S. A. 99:16412-16418.
31. Hazeki, N., Tukamoto, T., Goto, J., and Kanazawa, I. 2000. Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: applying to quantification of protein components of the aggregates. Biochem. Biophys. Res. Commun. 277:386-393.
32. Parker, J.A., et al. 2001. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc. Natl. Acad. Sci. U. S. A. 98:13318-13323.
33. Parker, J.A., et al. 2005. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 37:349-350.
34. Cheetham, M.E., Jackson, A.P., and Anderton, B.H. 1994. Regulation of 70-kDa heat-shock-protein ATPase activity and substrate binding by human DNAJ-like proteins, HSJ1a and HSJ1b. Eur. J. Biochem. 226:99-107.
35. Cheetham, M.E., Anderton, B.H., and Jackson, A.P. 1996. Inhibition of hsc70-catalysed clathrin uncoating by HSJ1 proteins. Biochem. J. 319:103-108.
36. Harjes, P., and Wanker, E.E. 2003. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 28:425-433.
37. Gleeson, P.A., Lock, J.G., Luke, M.R., and Stow, J.L. 2004. Domains of the TGN: coats, tethers and G proteins. Traffic. 5:315-326.
38. Infante, C., Ramos-Morales, F., Fedriani, C., Bornens, M., and Rios, R.M. 1999. GMAP-210, a cis-Golgi network-associated protein, is a minus end microtubule-binding protein. J. Cell Biol. 145:83-98.
39. Klausner, R.D., Donaldson, J.G., and Lippincott-Schwartz, J. 1992. Brefeldin A: insights into the control of membrane traffic and organelle structure. J. Cell Biol. 116:1071-1080.
40. Campisi, A., et al. 2003. Glutamate-induced increases in transglutaminase activity in primary cultures of astroglial cells. Brain Res. 978:24-30.
41. Pastuszko, A., Wilson, D.F., and Erecinska, M. 1986. A role for transglutaminase in neurotransmitter release by rat brain synaptosomes. J. Neurochem. 46:499-508.
42. Gahl, W.A., Thoene, J.G., and Schneider, J.A. 2002. Cystinosis. N. Engl. J. Med. 347:111-121.
43. Shults, C., et al. 1986. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology. 36:1099-1102.
44. Dubinsky, R., and Gray, C. 2005. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov. Disord. doi:10.1002/mds.20756.
45. Wheeler, V.C., et al. 2000. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock- in mice. Hum. Mol. Genet. 9:503-513.
46. Mangiarini, L., et al. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:493-506.
47. Wheeler, V.C., et al. 2002. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet. 11:633-640.
48. Brouillet, E., et al. 1995. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. U. S. A. 92:7105-7109.
49. Palfi, S., et al. 1998. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat. Med. 4:963-966.
50. Petrova, P., et al. 2003. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J. Mol. Neurosci. 20:173-188.
51. Legendre-Guillemin, V., et al. 2005. Huntingtin interacting protein 1 (HIP1) regulates clathrin assembly through direct binding to the regulatory region of the clathrin light chain. J. Biol. Chem. 280:6101-6108.
52. Chen, C.Y., and Brodsky, F.M. 2005. Huntingtin-interacting protein 1 (Hip1) and Hip1-related protein (Hip1R) bind the conserved sequence of clathrin light chains and thereby influence clathrin assembly in vitro and actin distribution in vivo. J. Biol. Chem. 280:6109-6117.
53. Bungay, P.J., Potter, J.M., and Griffin, M. 1984. The inhibition of glucose-stimulated insulin secretion by primary amines. A role for transglutaminase in the secretory mechanism. Biochem. J. 219:819-827.
54. Gobbi, M., Frittoli, E., and Mennini, T. 1996. Role of transglutaminase in [3H]5-HT release from synaptosomes and in the inhibitory effect of tetanus toxin. Neurochem. Int. 29:129-134.
55. Davies, P.J., et al. 1984. Studies on the effects of dansylcadaverine and related compounds on receptor-mediated endocytosis in cultured cells. Diabetes Care. 7:35-41.
56. Howe, C.L., Valletta, J.S., Rusnak, A.S., and Mobley, W.C. 2001. NGF signaling from clathrin-coated vesicles: evidence that signaling endosomes serve as a platform for the Ras-MAPK pathway. Neuron. 32:801-814.
57. Jeitner, T.M., Delikatny, E.J., Ahlqvist, J., Capper, H., and Cooper, A.J. 2005. Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem. Pharmacol. 69:961-970.
58. Tenneze, L., Daurat, V., Tibi, A., Chaumet-Riffaud, P., and Funck-Brentano, C. 1999. A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. Br. J. Clin. Pharmacol. 47:49-52.
59. Belldina, E.B., Huang, M.Y., Schneider, J.A., Brundage, R.C., and Tracy, T.S. 2003. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br. J. Clin. Pharmacol. 56:520-525.
60. Douma, S., et al. 2004. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 430:1034-1039.
61. Kleta, R., et al. 2004. Long-term follow-up of well-treated nephropathic cystinosis patients. J. Pediatr. 145:555-560.
62. Chun, W., et al. 2001. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells. Neurobiol. Dis. 8:391-404.
63. Cummings, C.J., et al. 1998. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19:148-154.
64. Haubensak, W., Narz, F., Heumann, R., and Lessmann, V. 1998. BDNF-GFP containing secretory granules are localized in the vicinity of synaptic junctions of cultured cortical neurons. J. Cell Sci. 111:1483-1493.
65. Humbert, S., et al. 2002. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell. 2:831-837.
66. Brenner, S. 1974. The genetics of Caenorhabditis elegans. Genetics. 77:71-94.
67. Metzler, M., et al. 2001. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J. Biol. Chem. 276:39271-39276.
68. Louvard, D., Reggio, H., and Warren, G. 1982. Antibodies to the Golgi complex and the rough endoplasmic reticulum. J. Cell Biol. 92:92-107.
69. Ernfors, P., Lee, K.F., and Jaenisch, R. 1994. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature. 368:147-150.
70. Perez-Navarro, E., Alberch, J., Neveu, I., and Arenas, E. 1999. Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo. Neuroscience. 91:1257-1264.